Aridis Pharmaceuticals, Inc.
ARDS
$0.0001
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 417.00K | 19.65M | 1.08M | 1.21M | 399.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 417.00K | 19.65M | 1.08M | 1.21M | 399.00K |
| Cost of Revenue | 175.00K | 4.67M | 5.53M | 6.78M | 6.12M |
| Gross Profit | 242.00K | 14.98M | -4.45M | -5.57M | -5.72M |
| SG&A Expenses | 1.11M | 1.31M | 1.81M | 1.63M | 1.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.29M | 5.98M | 7.35M | 8.41M | 7.81M |
| Operating Income | -869.00K | 13.67M | -6.26M | -7.19M | -7.41M |
| Income Before Tax | -83.00K | 12.14M | -6.82M | -6.39M | -8.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -83.00K | 12.14M | -6.82M | -6.39M | -8.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.00K | 12.14M | -6.82M | -6.39M | -8.24M |
| EBIT | -869.00K | 13.67M | -6.26M | -7.19M | -7.41M |
| EBITDA | -810.00K | 13.73M | -6.18M | -7.09M | -7.29M |
| EPS Basic | 0.00 | 0.34 | -0.22 | -0.29 | -0.47 |
| Normalized Basic EPS | -0.01 | 0.24 | -0.13 | -0.20 | -0.26 |
| EPS Diluted | 0.00 | 0.33 | -0.22 | -0.29 | -0.47 |
| Normalized Diluted EPS | -0.01 | 0.23 | -0.13 | -0.20 | -0.26 |
| Average Basic Shares Outstanding | 37.43M | 36.10M | 30.41M | 22.00M | 17.70M |
| Average Diluted Shares Outstanding | 37.43M | 36.60M | 30.41M | 22.00M | 17.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
